Drug Profile
Research programme: Alzheimer's disease therapeutic - PharmaMax
Alternative Names: CNS-300; CNS-301; CNS-302; CNS-303Latest Information Update: 28 Feb 2019
Price :
$50
*
At a glance
- Originator PharmaMax
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Feb 2019 No recent reports of development identified for clinical-Phase-Unknown development in Alzheimer's-disease in China